Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

NCT03862885 · clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Blueprint Medicines Corporation